- Home
- LOAN vs NRXP Comparison
LOAN vs NRXP Comparison
Compare LOAN & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOAN | NRXP |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.9M | 73.7M |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | LOAN | NRXP |
|---|---|---|
| Price | $4.78 | $2.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.50 |
| AVG Volume (30 Days) | 40.1K | ★ 446.3K |
| Earning Date | 10-24-2025 | 11-17-2025 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $7,138,128.00 | $242,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.47 | $643.59 |
| P/E Ratio | $10.09 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.29 | $1.15 |
| 52 Week High | $6.05 | $6.01 |
Technical Indicators
Market Signals| Indicator | LOAN | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 45.23 |
| Support Level | $4.64 | $2.22 |
| Resistance Level | $4.83 | $2.51 |
| Average True Range (ATR) | 0.14 | 0.19 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 74.77 | 68.52 |
Price Performance
Historical ComparisonAbout LOAN Manhattan Bridge Capital Inc
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.